The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; none of the 40 sources its claims cite is checked for support yet.
Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo
Open accessAbstract
The combination of Cas9, guide RNA and repair template DNA can induce precise gene editing and the correction of genetic diseases in adult mammals. However, clinical implementation of this technology requires safe and effective delivery of all of these components into the nuclei of the target tissue. Here, we combine lipid nanoparticle-mediated delivery of Cas9 mRNA with adeno-associated viruses encoding a sgRNA and a repair template to induce repair of a disease gene in adult animals. We applied our delivery strategy to a mouse model of human hereditary tyrosinemia and show that the treatment generated fumarylacetoacetate hydrolase (Fah)-positive hepatocytes by correcting the causative Fah-splicing mutation. Treatment rescued disease symptoms such as weight loss and liver damage. The efficiency of correction was >6% of hepatocytes after a single application, suggesting potential utility of Cas9-based therapeutic genome editing for a range of diseases.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This study combined lipid nanoparticle delivery of Cas9 mRNA with AAV-delivered sgRNA and an HDR template to correct the Fah mutation in a mouse model of hereditary tyrosinemia type I. A single treatment corrected >6% of hepatocytes, restored Fah splicing, and rescued weight loss and liver damage.
Key findings
- In Fahmut/mut mice, combined nano.Cas9 + AAV-HDR treatment yielded 6.2% ± 1.0% Fah-positive hepatocytes by immunohistochemistry after a single application (n = 4 mice), with correction correlating with nano.Cas9 and AAV-HDR dose.
- Treated mice had 9.5% restored FAH mRNA without selection, 24.1% average indels at the sgRNA target region, and 0.81% ± 0.08% corrected “G-CC” sequence in total liver DNA by deep sequencing.
- Treatment completely prevented body weight loss after NTBC withdrawal, all nano.Cas9 + AAV-HDR mice survived 30 days, and serum AST, ALT, and bilirubin indicated substantially reduced liver damage compared with controls.
- Off-target editing was low at assayed sites: <0.3% indels at three top predicted off-target sites, and in vivo OT1/GOT sites were not substantially higher than background (P > 0.05); transient mRNA Cas9 also reduced off-target editing versus long-term lentiviral Cas9 in cells.
Methods
- Fahmut/mut mice (8–10 weeks old, male and female) were injected via tail vein with AAV2/8-HDR (6 × 10^11 or 1.2 × 10^12 genome copies) and nano.Cas9 (1 or 2 mg/kg); in the efficacy experiment, AAV-HDR was given at day −14, nano.Cas9 at day −7, and NTBC water was withdrawn at day 0.
- Cas9 mRNA was chemically modified and formulated with C12-200, cholesterol, C14PEG2000, DOPE, and arachidonic acid in lipid nanoparticles; AAV-HDR encoded U6-sgRNA and a 1.7-kb HDR template designed to correct the mutant “A” to wild-type “G” and introduce a “CC” PAM motif.
- Analyses included liver immunohistochemistry, serum biomarkers, qRT-PCR, Sanger sequencing, Illumina deep sequencing, GUIDE-Seq in Hepa1-6 cells, and statistics by Student’s t-tests and one-way ANOVA with Tukey post-test.
Limitations
- Stated: non-viral delivery of DNA into the nucleus in vivo with high efficiency and low toxicity remains difficult, and further improvement of HDR efficacy may require optimizing HDR template design and inhibiting the NHEJ pathway.
- Stated: the stringent “G-CC” pattern counting may underestimate HDR events, and an alternative explanation for the observed data is partial gene conversion; off-target analysis was limited to predicted and assayed sites.
- Evident from the text: efficacy was shown only in the Fahmut/mut mouse model, with small group sizes (n = 3–4 mice) and 30-day follow-up, so long-term durability, AAV immunogenicity, and human translation are not established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 40 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The analysis of deep sequencing data confirmed a corrected “G-CC” pattern at the Fah locus in 0.81% ± 0.08% of the total liver DNA, in contrast to the AAV-HDR alone group, which contained no detectable “G-CC” sequences (Fig. 3g).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Here we report that systemic delivery of Cas9 mRNA by lipid nanoparticles and sgRNA/HDR template by AAV can efficiently cure Fahmut/mut mice.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observed insertional or deletional mutations (indels) surrounding the Cas9 cleavage site (Fig. 1c–e and Supplementary Table 3).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The number of Fah-positive hepatocytes correlated with the dose of nano.Cas9 and AAV-HDR (Fig. 3c).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“To determine whether lipid nanoparticles can deliver Cas9 mRNA, nano.Cas9 (1 mg/kg or 2 mg/kg) was injected intravenously, and Cas9 protein in total liver lysates was detected by immunoblot (Supplementary Fig. 2d).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observed a number of GUIDE-Seq oligonucleotide integration sites within the genome (Supplementary Table 7) but only the Fah target site and one other site (OT1, which is also the computationally predicted off-target site with the fewest mismatches in the genome; Supplementary Fig. 7) passed our stringent criteria for potential nuclease cleavage sites (Supplementary Table 8).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, at least for Ctnnb1, the all-viral Cas9 delivery did not significantly increase the HDR rate compared to mRNA delivery.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At 30 d after NTBC water withdrawal, serum biomarkers (AST, ALT and bilirubin) indicated that liver damage was substantially reduced in nano.Cas9 + AAV-HDR–treated mice compared to control mice (Fig. 2c).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observed an average of 24.1% indels at predicted sgRNA target region within nano.Cas9 (2 mg/kg) + AAV-HDR group (1.2 × 1012) (Fig. 3f and Supplementary Table 5) (n = 4 mice).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All the mice in the nano.Cas9 + AAV-HDR group survived 30 d after NTBC withdrawal.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- Probably not a substantial claim. 15
- It may state two separate claims as one. 28
- The quote only partly states this claim. 1
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean particle diameter of nano.Cas9 is about 120 nm as determined by dynamic light scattering (Supplementary Fig. 1c).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compared to indels at the on-target Fah site (Fig. 3f), <0.3% indels were detected at the assayed off-target sites in nano.Cas9 + AAV-HDR–treated mice, and these numbers were comparable with AAV-HDR–treated control mice (Supplementary Fig. 7 and Supplementary Table 6), indicating that Cas9 mRNA delivery has minimal off-target effects at assayed sites for Fah sgRNA.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“OT1 and several other assayed sites had modest indel rates, and none of these sites were substantially higher than the background indel rate in untreated livers (P > 0.05; Supplementary Fig. 8b and Supplementary Table 9).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observed ∼24% indels and ∼1.2% beta-Catenin–positive hepatocytes in vivo (Supplementary Fig. 6).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observed a clear band in livers of nano.Cas9 + AAV-HDR–treated animals, but not in control animals (Supplementary Fig. 5b). We sequenced the band and identified that the corrected sequence (“G-CC” pattern) is integrated (Supplementary Fig. 5c).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These additional sites did not meet our peak calling criteria, but we detected 2.4% and 1.8% indels at OT1 in two replicates (Supplementary Fig. 8a and Supplementary Table 9), consistent with OT1 being a Cas9:sgFah off-target site in transformed cells in vitro.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Cas9 mRNA was present in the liver at 4 h and 14 h but was significantly diminished at 24 h (P < 0.05), consistent with transient expression (Supplementary Fig. 2e).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found sgRNA was already expressed at day 3, but its levels were more than tenfold higher at day 7 and day 14.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The efficiency of correction was >6% of hepatocytes after a single application, suggesting potential utility of Cas9-based therapeutic genome editing for a range of diseases.”
- Also stated in: § Abstract · plain
“Up to 6.2% ± 1.0% hepatocytes stained positive for the Fah protein by immunohistochemistry in nano.Cas9 plus AAV-HDR–treated animals (Fig. 3b,c; n = 4 mice; see Supplementary Table 4 for percentage of Fah-positive cells, age and gender of each mouse).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The particle size of nano.Cas9 was the same on day 0, 7, 11 and 18 (Supplementary Fig. 1d,e), indicating these particles are stable for at least 18 d in PBS.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“β-gal protein was detected in the mouse liver by immunoblot at 14 h after administration of a single dose (1 mg/kg or 2 mg/kg), and the amount of protein expressed correlated with the dose of mRNA (Supplementary Fig. 2b).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Most indels are frameshift (e.g., 1 nt and 2 nt) mutations (Fig. 1e), which potentially cause loss of function of the GFP reporter.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Systemic delivery of Cas9 mRNA by lipid nanoparticles, and sgRNA/HDR template by AAV, corrected a Fah mutation and restored Fah splicing in more than 6% of hepatocytes in the adult mouse liver, an order of magnitude improvement over that previously generated using high-pressure injection of DNA16.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [16] Yin, H. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551–553 (2014). source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This treatment is well-tolerated in mice and fully rescued body weight loss and liver damage in tyrosinemia mice.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The majority of the cells in liver sections stained positive in a β-gal activity assay (Supplementary Fig. 2c), indicating systemic delivery of mRNA to most of the cells in the mouse liver.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In HTI patients, mutation of fumarylacetoacetate hydrolase (FAH), the last enzyme catalyzing the tyrosine catabolic pathway, leads to accumulation of toxic metabolites and severe liver damage8.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [8] Paulk, N.K. et al. Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology 51, 1200–1208 (2010). source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The Fahmut/mut mouse model6,8 is caused by a G→A point mutation in the last nucleotide of exon 8. This causes skipping of exon 8 and truncated Fah mRNA.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [6] Aponte, J.L. et al. Point mutations in the murine fumarylacetoacetate hydrolase gene: animal models for the human genetic disorder hereditary tyrosinemia type 1. Proc. Natl. Acad. Sci. USA 98, 641–645 (2001). source
- Not checked yetcites [8] Paulk, N.K. et al. Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology 51, 1200–1208 (2010). source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“An alternative approach is the non-viral delivery of Cas9 mRNA, which would allow for short-term expression and, eventually, complete removal of the nuclease from the body.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“However, all of these delivery studies have reported gene knockout rather than gene repair, a less efficient process requiring a DNA repair template15.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [15] Chu, V.T., Weber, T. & Wefers, B. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat. Biotechnol. 33, 543–548 (2015). source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Cas9:sgRNA recognizes the protospacer-adjacent motif (PAM) sequence and a complementary 20-nucleotide genomic sequence and induces double-strand DNA breaks, which are repaired by error-prone nonhomologous end-joining (NHEJ) or precise homology-directed repair (HDR)2,5.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [2] Doudna, J.A. & Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096 (2014). source
- Not checked yetcites [5] Sander, J.D. & Joung, J.K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 32, 347–355 (2014). source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“Recently, a smaller form of Cas9 was developed, and shown capable of packing and delivery with sgRNA by AAV in vivo12.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [12] Ran, F.A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186–191 (2015). source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Lipid and lipid-like formulations have shown great promise as delivery agents for siRNA in a range of species, including humans19.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [19] Yin, H. et al. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541–555 (2014). source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Nevertheless, hydrodynamic injection yielded a low correction rate of 0.4% of hepatocytes, and this method has been tested in only one human clinical trial17.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [16] Yin, H. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551–553 (2014). source
- Not checked yetcites [17] Khorsandi, S.E. et al. Minimally invasive and selective hydrodynamic gene therapy of liver segments in the pig and human. Cancer Gene Ther. 15, 225–230 (2008). source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“However, AAV has a loading capacity size of approximately 4.7 kb, and the most commonly used form of Cas9 from Streptococcus pyogenes is difficult to fit in typical AAV constructs with efficient promoters13.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [13] Swiech, L. et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol. 33, 102–106 (2015). source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“These mice can be treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), an inhibitor of an enzyme upstream of Fah, to prevent toxin accumulation in hepatocytes8.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [8] Paulk, N.K. et al. Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology 51, 1200–1208 (2010). source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“To express sgRNA, we treated animals with up to 1.2 × 1012 AAV genome copies/mouse, a standard dose described in the literature28.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [28] Barzel, A. et al. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature 517, 360–364 (2015). source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This allowed for short-term expression of the Cas9 nuclease, which provided efficient on-target genome editing, while potentially reducing off-target editing (Fig. 1h).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A smaller form of Cas9 (Staphylococcus aureus Cas9), which fits into AAV vectors, has been recently used to knockout genes by NHEJ in the mouse liver. More than 40% indel formations in Pcsk9 locus was reported12.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [12] Ran, F.A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186–191 (2015). source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All animal experiments were performed under the guideline of the MIT Animal Care and Use Committee.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Online Methods > Animal experiments
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This estimation is consistent with the 0.81% corrected “G-CC” sequence pattern observed by deep sequencing in treated liver samples (Fig. 3g).”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe quote only partly states this claim.
In the paper
“A recent study demonstrated that the chemical modification of sgRNA improved gene editing in vitro when co-delivered with Cas9 mRNA32.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [32] Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985–989 (2015). source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“A key feature of our system is the transient expression of the nuclease Cas9, through delivery of mRNA. This allowed for sufficient exposure to the nuclease for gene repair and reduced concerns associated with long-term nuclease exposure34.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [34] Wu, X. et al. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat. Biotechnol. 32, 670–676 (2014). source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The CRISPR systems have a number of potential advantages over ZFNs, most importantly their flexibility and ease in adjusting target site4.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [4] Mali, P., Esvelt, K.M. & Church, G.M. Cas9 as a versatile tool for engineering biology. Nat. Methods 10, 957–963 (2013). source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“However, correction of 6% of hepatocytes following a single round of treatment without selection suggests that this approach may be suitable for the treatment of a range of metabolic liver diseases and hemophilia, where restoration of 3–7% normal functional protein can be therapeutic39.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [39] Cox, D.B., Platt, R.J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121–131 (2015). source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“An alternative explanation for this observation is partial gene conversion in spite of “G” and “CC” single-nucleotide polymorphisms equidistant to the Cas9 cutting site.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [36] Elliott, B., Richardson, C., Winderbaum, J., Nickoloff, J.A. & Jasin, M. Gene conversion tracts from double-strand break repair in mammalian cells. Mol. Cell. Biol. 18, 93–101 (1998). source
- Not checked yetcites [37] Goldberg, A.D. et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 140, 678–691 (2010). source
- Not checked yetcites [38] Findlay, G.M., Boyle, E.A., Hause, R.J., Klein, J.C. & Shendure, J. Saturation editing of genomic regions by multiplex homology-directed repair. Nature 513, 120–123 (2014). source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Previous work has reported on the use of zinc finger nucleases (ZFNs) for in vivo gene correction31,33.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [31] Mahiny, A.J. et al. In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency. Nat. Biotechnol. 33, 584–586 (2015). source
- Not checked yetcites [33] Li, H. et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475, 217–221 (2011). source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It is possible that our stringent “G-CC” pattern counting underestimated the HDR event.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Although NHEJ has been reported using AAV-mediated Cas9 delivery, HDR using viral delivery in vivo has not been reported.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Cells were tested by MIT core facility for mycoplasma contamination by an ELISA-based assay, and confirmed negative.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Online Methods > Cell culture, off-target analysis and Illumina sequencing
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“For example, less than 10% indels at the Apob locus in the mouse liver was reported in the same study12.”
§ Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo > Abstract
What the sources say
- Not checked yetcites [12] Ran, F.A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186–191 (2015). source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
Clinical implementation of CRISPR genome editing requires safe and effective delivery of all components into the nuclei of the target tissue.
“However, clinical implementation of this technology requires safe and effective delivery of all of these components into the nuclei of the target tissue.”
The paper relies on this without support.
Improvements to CRISPR delivery methods and HDR efficiency are required for therapeutic application of genome editing for disease gene correction.
“However, improvements to CRISPR delivery methods and HDR efficiency are required for therapeutic application of genome editing for disease gene correction.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“If delivering Cas9 mRNA and sgRNA, this method is functionally like microinjection in result (Yin et al., 2016).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Yin et al., 2016
Experimental — accuracy not yet measuredIn the citing paper
“Gene-editing components can be delivered by lipid nanoparticle–mRNA formulations to treat genetic diseases, including HTI92,238, hypercholesterolaemia81,96,105,239, lipoprotein metabolism disorders85 and transthyretin amyloidosis239,240, which has been demonstrated in preclinical studies.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [92]
In the citing paper
“We and others recently reported that CRISPR can correct this Fah mutation through HDR16–18 or allelic exchange19.”
From Adenine base editing in an adult mouse model of tyrosinaemia (2019) · cites this paper as [16]
In the citing paper
“Using the standard Guide-seq protocol, we detected only the Fah target site and one off-target site (defined as Guide-seq off-target site 1, or GOT1) (Supplementary Data Set 1).”
From Adenine base editing in an adult mouse model of tyrosinaemia (2019) · cites this paper as [16]
In the citing paper
“After a single treatment, the FAH expression in more than 6% of hepatocytes was repaired and the symptoms of hepatic damage were prevented in the following 30 days.”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [141]
In the citing paper
“Yin et al. combined lipid nanoparticle-mediated delivery of Cas9 mRNA with AAV encoding sgRNAs and donor templates to repair FAH gene in a mouse model of human hereditary tyrosinemia. The efficiency of correction was >6% of hepatocytes after a single application and the treatment rescued disease symptoms such as weight loss and liver damage [112].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [112]
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationCRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696
Organoid Models and Applications in Biomedical Research
Xinaris, C., Brizi, V., & Remuzzi, G. (2015) · The Nephron journals/Nephron journals · doi:10.1159/000433566 · Cited by 3,519
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Self-citationIn vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 874
Nanoscale delivery of phytochemicals targeting CRISPR/Cas9 for cancer therapy
Hussain, Y., Khan, H. Z., Ahmad, I. I., Efferth, T., & Alam, W. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153830 · Cited by 5
Lu, L., Rao, D., Niu, C., Cheng, L., Ma, D., & Xi, Z. (2022) · ChemBioChem · doi:10.1002/cbic.202100544 · Cited by 5
Gene Therapy in Tyrosinemia: Potential and Pitfalls
Carter, S., & Doyon, Y. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_21 · Cited by 5
Current and Future Therapeutic Strategies for Lentiviral Eradication from Macrophage Reservoirs
Peterson, T. A., & MacLean, A. G. (2018) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-018-9814-5 · Cited by 6
Thiourea-Functional Bioreducible Poly(amido amine)s in Gene Delivery
Elzes, M. R., Si, G., Engbersen, J. F. J., & Paulusse, J. M. J. (2019) · ACS symposium series · doi:10.1021/bk-2019-1309.ch005 · Cited by 5
CRISPR–Cas Gene Editing for Neurological Disease
Simpson, B. P., & Davidson, B. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813997-4.00018-9 · Cited by 5
Bi, Y., Gu, L., Wang, J., Chang, Y. P., Jin, M., Mao, Y., Wang, H., & Ji, G. (2021) · The CRISPR Journal · doi:10.1089/crispr.2020.0110 · Cited by 5
Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system
Hajifathali, A., Lasemi, M. V., Mehravar, M., Moshari, M. R., Alizadeh, A. M., & Roshandel, E. (2023) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2023.05.009 · Cited by 5
Edição de genes CRISPR-Cas9 e suas aplicações terapêuticas: Uma revisão de literatura
Mendes, L. M. C., Lino, L. A., Bordignon, T. M., de Castro, M. M., Bartholomeu, L. M. D. D. O., de Almeida, Z. S., Carneiro, I. M. V., da Silva, I. M., Martins, I. D. R., Honorato, M. P. P., et al. (2024) · Research Society and Development · doi:10.33448/rsd-v13i8.46681 · Cited by 4
Progress in Gene Therapy for Hereditary Tyrosinemia Type 1
Thomas, H., & Carlisle, R. C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030387 · Cited by 4
CRISPR-Cas9-Loaded Lipid Nanoparticles: A Promising Strategy for Targeted Gene Editing and Therapy
Ebrahimi-Khezrabad, S., Aghdasia, M., Zare‐Zardini, H., Eslami, H., & Eskandari, F. (2025) · BioNanoScience · doi:10.1007/s12668-025-02094-z · Cited by 5
In vivo gene therapy: A strategy for mutations, degenerations, and tumors
Wang, T., Yu, M., Liu, P., Song, Z., Li, C., Yang, J., & Liu, N. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101808 · Cited by 4
Self-citationJanich, C., Ivanusic, D., Giselbrecht, J., Janich, E., Pinnapireddy, S. R., Hause, G., Bakowsky, U., Langner, A., & Wölk, C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090805 · Cited by 4
Polymer-Based Transfection Agents Used in CRISPR-CAS9 System
İmamoğlu, R., Kaplan, Ö., Gök, M. K., & Gökçe, İ. (2022) · Türk doğa ve fen dergisi :/Türk doğa ve fen dergisi · doi:10.46810/tdfd.795053 · Cited by 4
Croteau, F. R., Rousseau, G. M., & Moineau, S. (2018) · médecine/sciences · doi:10.1051/medsci/2018215 · Cited by 7
Gene editing based hearing impairment research and therapeutics
Kang, W., Sun, Z., Zhao, X., Wang, X., Tao, Y., & Wu, H. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134326 · Cited by 4
Shi, P., Tang, B., Zhou, S., Qin, J., Zan, X., & Geng, W. (2021) · Biomaterials Science · doi:10.1039/d1bm00063b · Cited by 4
Modulation of Immune Reaction in Hydrodynamic Gene Therapy for Hemophilia A
Zhao, M., Sun, Y., Yin, M., Zhao, J.-J., Li, S.-A., Li, G., Zhang, F., Xu, J., Meng, F., Zhang, B., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.145 · Cited by 4
Brunetti‐Pierri, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817344-2.00030-7 · Cited by 4
Mustafa, F. (2021) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2021.40.006432 · Cited by 4
Future Approaches in Liver Disorders: Regenerative Medicine
Jinga, M., Balaban, D. V., Bontaş, E., & Tintoiu, I. (2020) · Springer eBooks · doi:10.1007/978-3-030-24432-3_74 · Cited by 4
Odabaş, S. P., Bal, E., Yelgen, G., Metin, A. S., Karakaya, E., Gülden, G., Sert, B., Teymur, T., Ay, Y., Tiryaki, N. N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.21.484406 · Cited by 4
Cas9 Protein Outperforms mRNA in Lipid Nanoparticle-Mediated CFTR Repair
Joseph, R. A., Haley, R. M., Padilla, M. S., Ricciardi, A. S., Yamagata, H. M., & Mitchell, M. J. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c03548 · Cited by 3
Jin, X., Wu, X., Song, J., Luo, M., Ye, Q., Ren, C., Li, S., Li, M., Hu, M., An, Y., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.012 · Cited by 3
Non-viral delivery of genome-editing tools for treatment of genetic disorders
Yang, J., Chen, Y., Chen, X., & Ping, Y. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.02.014 · Cited by 3
Self-citationApplications of genome editing technologies in the treatment of human diseases
Alshorman, J., Mehran, M. J., Tembo, K. M., Mostafavi, N., Bolideei, M., & Wang, Y. L. (2026) · Gene Therapy · doi:10.1038/s41434-026-00627-z · Cited by 3
Bingxue, D., Wenchao, L., & Xing, B. (2022) · Springer eBooks · doi:10.1007/978-981-16-1313-5_74-1 · Cited by 3
Genome engineering with Cas9 and AAV repair templates, successes and pitfalls
Birling, M., Hérault, Y., & Pavlovic, G. (2025) · Mammalian Genome · doi:10.1007/s00335-024-10099-4 · Cited by 3
Nanotechnology-Based Targeted Drug Delivery Systems for Cancer Treatment
Jin, Y. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.19722 · Cited by 3
Clinical and biochemical footprints of inherited metabolic diseases: Ia. Movement disorders, updated
Peacock, D. J. S. J., Ferreira, C. R., Horvath, G. A., Hoffmann, G. F., Blau, N., & Ebrahimi‐Fakhari, D. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109084 · Cited by 4
CRISPR Technology in Antiviral Therapy: Advancements, Applications, and Implications
Kulkarni, C. R., Prajnashree, A., & Nyamagoud, S. B. (2025) · D Y Patil Journal of Health Sciences · doi:10.4103/dypj.dypj_2_25 · Cited by 3
RNA-based CRISPR-Mediated Loss-of-Function Mutagenesis in Human Pluripotent Stem Cells
Leung, A. W., Broton, C., Bogacheva, M. S., Xiao, A., García‐Castro, M. I., & Lou, Y. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.04.017 · Cited by 3
Activation of homology-directed DNA repair plays key role in CRISPR-mediated genome correction
Mondal, G., VanLith, C. J., Nicolas, C. T., Thompson, W. S., Cao, W., Hillin, L. G., Haugo, B. J., Brien, D. R. O., Kocher, J., Kaiser, R. A., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00369-8 · Cited by 3
Polymer-Mediated Delivery of CRISPR-Cas9 Genome-Editing Therapeutics for CNS Disease
Iqbal, S., Alexander-Bryant, A. A., & Larsen, J. (2022) · Springer eBooks · doi:10.1007/978-3-031-11409-0_6 · Cited by 3
Genome Editing advances in Soybean Improvement against Biotic and Abiotic Stresses
Aslam, S., Munir, A., Aslam, H. M. U., Khan, S. H., & Ahmad, A. (2022) · Springer eBooks · doi:10.1007/978-3-031-12232-3_13 · Cited by 3
CRISPR/Cas9 Technology: Challenges and drawbacks
Ghorui, S. B. A. (2023) · Journal Of Advanced Zoology · doi:10.17762/jaz.v44is6.2680 · Cited by 3
Oh, N., & Kim, J. Y. (2025) · ACS Nano · doi:10.1021/acsnano.5c02283 · Cited by 3
Therapeutic Gene Editing in Muscles and Muscle Stem Cells
Tabebordbar, M., Cheng, J. K. W., & Wagers, A. J. (2017) · Research and perspectives in neurosciences · doi:10.1007/978-3-319-60192-2_10 · Cited by 3
Genome Editing for Duchenne Muscular Dystrophy
Nelson, C. E., & Gersbach, C. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_22 · Cited by 4
Key to Delivery: The (Epi-)genome Editing Vector Toolbox
Just, S., & Büning, H. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7774-1_7 · Cited by 3
Jacobson, J. M., & Khalili, K. (2018) · Aids Reviews · doi:10.24875/aidsrev.18000027 · Cited by 3
Muscular Dystrophy Therapy Using Viral Vector-based CRISPR/Cas
Choi, E., & Koo, T. (2022) · Springer eBooks · doi:10.1007/978-3-030-93333-3_4 · Cited by 3
Polymeric Nanoparticles for Cancer Gene Therapy
Moku, G. (2021) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2021.34.005563 · Cited by 3
Nucleic acids based integrated macromolecular complexes for SiRNA delivery: Recent advancements
Singh, D., Singh, L., Kaur, S., & Arora, A. (2024) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2024.2347499 · Cited by 2
Bhardwaj, A., Verma, S., Agnihotri, A., & Chitme, H. R. (2025) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2025.2548844 · Cited by 2
Nanoparticle-driven CRISPR-Cas9 genome editing: a new frontier in crop improvement
Gupta, I., Sharma, J. G., & Kaul, T. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11064-3 · Cited by 2
Shamsi, A., Alrouji, M., AlOmeir, O., Tasqeruddin, S., Khuzin, D., & Zuberi, A. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1681891 · Cited by 2
Characterization and engineering of highly efficient Cas12j genome editors
Rao, G. S., Jiang, W., Aouida, M., Wang, Q., Kazlak, A. M., Elbehery, A. H. A., Saleh, A., Masood, M., Ghouneimy, A., & Mahfouz, M. E. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2026.02.001 · Cited by 2
Madsen, A., Selfjord, N., Martínez-Lage, M., Loyd, A.-L., Kurgan, G., Stahlberg, M., Lindgren, J., Touza, J. L., Wigge, L., Firth, M. A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-77144-5 · Cited by 2
The applications and advances of CRISPR-Cas9 in medical research
Lu, X., Sun, H., Xu, Y. J., Xi, Y., & Gu, B. (2016) · Briefings in Functional Genomics · doi:10.1093/bfgp/elw036 · Cited by 2
Point: Treating Human Genetic Disease One Base Pair at a Time: The Benefits of Gene Editing
Katsanis, N. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.278309 · Cited by 2
Syaharani, R., Adhima, F., Amru, S. N., & I’tishom, R. (2021) · International Journal of Research Publications · doi:10.47119/ijrp100921120222750 · Cited by 2
Novel Nanotechnology-Based Vector Delivery in CRISPR System for Transgene-Free Editing
Saeed, S., Ahmed, A., Nizamuddin, S., Qureshi, S. S., Shahzad, R., Khan, N. U., Shaban, M., Khan, M. H. U., & Khan, S. U. (2022) · Springer eBooks · doi:10.1007/978-3-030-96925-7_12 · Cited by 2
Recent advances in CRISPR-Cas system for the treatment of genetic hearing loss.
Yin, G., Wang, X., & Sun, Y. (2023) · PubMed Central · Cited by 3
(2024) · CABI biotechnology series. · doi:10.1079/9781800626638.0000 · Cited by 2
The approaches and challenges in delivery CRISPR/Cas9
Zhang, Z. (2024) · Theoretical and Natural Science · doi:10.54254/2753-8818/35/20240911 · Cited by 2
De, S., Rai, V., Ahmed, F., Basak, M., & Bose, S. (2024) · Journal of Maxillofacial and Oral Surgery · doi:10.1007/s12663-024-02348-5 · Cited by 2
Modeling Cancer Using CRISPR-Cas9 Technology
Rodríguez, S., Martínez-Lage, M., & Torres-Ruiz, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809468-6.00034-6 · Cited by 2
CRISPR-Cas9 in cancer therapeutics
Randhawa, S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.016 · Cited by 2
Recent developments in genome design and assembly tools
Barreiro, C., & García‐Estrada, C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824469-2.00012-9 · Cited by 3
Gene Editing in Regenerative Medicine
Fang, Y., Chen, X., & Godbey, W. T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809880-6.00042-4 · Cited by 2
Emerging CRISPR/Cas9 applications for T-cell gene editing
Preece, R., & Georgiadis, C. (2019) · Emerging Topics in Life Sciences · doi:10.1042/etls20180144 · Cited by 2
CRISPR/Cas9 Editing in Induced Pluripotent Stem Cells: A Way Forward for Treating Cystic Fibrosis?
Quiroz, E. J., & Ryan, A. L. (2019) · Springer eBooks · doi:10.1007/978-3-030-29403-8_9 · Cited by 2
CRISPR-Cas9 system “a mighty player in cancer therapy”
Manvati, S., & Dhar, P. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818140-9.00008-8 · Cited by 2
Co-opting regulation bypass repair as a gene-correction strategy for monogenic diseases
Hu, J., Bourne, R. A., McGrath, B. C., Lin, A., Pei, Z., & Cavener, D. R. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.017 · Cited by 2
CRISPR/Cas System and Stem Cell Editing: Prospects and Possibilities in Veterinary Sciences
Hussain, M. S., & Kumar, M. (2021) · Springer eBooks · doi:10.1007/978-981-16-3464-2_18 · Cited by 2
Considerations for Cardiac CRISPR
Carroll, K. J., & Olson, E. N. (2017) · Circulation Research · doi:10.1161/circresaha.117.311974 · Cited by 2
Evolution of prime editing systems: move forward to the treatment of hereditary diseases
Volodina, O. V., Fabrichnikova, A. R., Anuchina, A. A., Mishina, O. S., Lavrov, A. V., & Smirnikhina, S. A. (2025) · Current Gene Therapy · doi:10.2174/0115665232295117240405070809 · Cited by 1
Cancer Therapy with CRISPR/Cas9: Prospects and Challenges
Chaudhary, M. F., Saleem, U., Khan, S., Khan, R., Asim, M., Azam, F., Sharif, M., Zainab, Z., Dilawar, A. A., & Jehanzaib, M. (2021) · International Journal of Environment Agriculture and Biotechnology · doi:10.22161/ijeab.63.16 · Cited by 1
Vijay, U., Pappu, P., Madduru, D., Stephen, N. B., Suravajhala, P., & Bandapalli, O. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-98806-3.00008-8 · Cited by 1
Koutsoni, E., Konstantakos, V., Nentidis, A., Krithara, A., & Παλιούρας, Γ. (2022) · Hellenic Conference on Artificial Intelligence · doi:10.1145/3549737.3549747 · Cited by 1
CRISPR-Cas9-based Strategies for Acute Lymphoblastic Leukemia Therapy
Becerra, E., Soto-Ontiveros, V., & García‐Alcocer, G. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106702 · Cited by 1
Advanced drug delivery systems for enhancing the efficacy of RNA-based therapeutics
Alhabib, N. A., Almaniea, M. A., Alehaidib, S. M., Almansour, M. A., Aldosary, M. S., Almegbel, M. T., Alsubaie, S. A., & Alzahrani, A. M. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns10.15029 · Cited by 1
Next‐Generation Bio‐Reducible Lipids Enable Enhanced Vaccine Efficacy in Malaria and Primate Models
Coen, R. D., Kasmi, S., Dumbre, S. G., Baekens, L., Seynaeve, E., den Hauwe, L. V., Cantini, N., Garantoudi, A., Madeira, F. B., Marrot, A., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202509838 · Cited by 1
Singh, M., Singh, I., Singh, P., Singh, D. K., Kumar, A., Singh, N. K., Iftikar, W., Sharma, S., Kumar, P., & Chaudhary, S. (2025) · Springer eBooks · doi:10.1007/978-981-95-1418-2_5 · Cited by 1
LNP-mRNA vaccines: Revolutionizing preventive medicine
Bhowmik, S., Kundu, S., Ghosh, S., Chowdhury, A. A., & Acharya, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45006-8.00007-0 · Cited by 1
Singh, R., Pandey, S., Pandey, A., & Kumar, G. (2025) · CABI biotechnology series. · doi:10.1079/9781800626638.0001 · Cited by 1
TARGETED DRUG DELIVERY THROUGH CRISPR‒CAS9: BRIDGING BIOPHARMACEUTICS AND PHARMACOKINETICS
Ramasamy, J., Jaisankar, D., RAMAMOORTHY, S., Jothibasu, D., & RAVIKUMAR, N. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i5.54502 · Cited by 1
Nanocarriers for the delivery of the CRISPR/Cas9 system
Hwang, S., Ko, H., Lee, H.-Y., & Choi, J. H. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2598332 · Cited by 1
Li, Y., Ma, S., & Fei, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083371 · Cited by 1
Self-citationNext-Generation Therapies for Genetic Diseases: The Synergy of CRISPR and Gene Therapy
Karwa, P. N., Kharul, A., Parekar, V., Labhade, S., Sakle, N. S., Bhole, R. P., & Kapare, H. S. (2026) · Biochemical Genetics · doi:10.1007/s10528-026-11378-2 · Cited by 1
du Plessis, J., & Omar, A. (2026) · Cancer Medicine · doi:10.1002/cam4.72112 · Cited by 1
Targeted Therapeutic Genome Engineering: Opportunities and Bottlenecks in Medical Translation
Kretzmann, J. A., Luther, D. C., Nörret, M., Rotello, V. M., & Iyer, K. S. (2019) · ACS symposium series · doi:10.1021/bk-2019-1309.ch001 · Cited by 1
Research progress on non-viral vectors of CRISPR/Cas9 system
Liu, Q., Zhang, Z., & Liu, Y. (2019) · Scientia Sinica Chimica · doi:10.1360/n032018-00233 · Cited by 1
Trends in CRISPR-Cas9 technology application in cancer
Mukhopadhyay, S., & Bhutia, S. K. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.12.004 · Cited by 1
Nagamoto, S., Agawa, M., Tsuchitani, E., Akimoto, K., Matsushima, S. K., & Kanegae, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-03803-w · Cited by 1
CRISPR-Cas Technology, the Tool of the Future
Alvarez, A. E., Morales, E. Q., Calero, M. P. V., Brenes, D. M., Salas, M. F. R., Redondo, G. M., Rojas, M. C., & Viales, E. B. (2022) · European Journal of Biology and Biotechnology · doi:10.24018/ejbio.2022.3.2.332 · Cited by 1
Worgall, S., & Crystal, R. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00029-0 · Cited by 1
Leukemia - From Biology to Clinic
Guenova, M. L., & Balatzenko, G. N. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100848 · Cited by 1
Advancements of CRISPR/Cas9 technology and its value in antiviral therapeutics
Dev, K., Begum, J., Mir, N. A., & Kant, R. (2021) · Letters In Animal Biology · doi:10.62310/liab.v1i1.60 · Cited by 1
Gene Therapies in the Fight against Liver Disease: A Comprehensive Review
Leff, P., Aboona, M. B., Choday, S., Ali, Q., Wijarnpreecha, K., & Alkhouri, N. (2024) · Journal of Advances in Medicine and Medical Research · doi:10.9734/jammr/2024/v36i55413 · Cited by 1
李, 大., 刘, 明., 王, 立., & 张, 晓. (2017) · Scientia Sinica Vitae · doi:10.1360/n052017-00208 · Cited by 1
Biomolecular Therapeutics for HIV
Li, S., & Burnett, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-50878-0.00018-5 · Cited by 1
HBV enfeksiyonunun tedavisinde CRISPR / Cas9 gen düzenleme sisteminin kullanımı
Alpaslan, M. K. (2020) · Gene Editing · doi:10.29228/genediting.40389 · Cited by 1
AIDS tedavisi için gen düzenleme çalışmaları
Akpınaroğlu, C. (2020) · Gene Editing · doi:10.29228/genediting.40387 · Cited by 1
Fu, J., Feng, S., Du, B., Dong, H., Lin, J., & Yongfeng, J. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0376 · Cited by 1
Gene Therapy in Liver Disease: Challenges and Outcomes
Premkumar, M., & Singh, V. (2022) · Springer eBooks · doi:10.1007/978-981-16-8845-4_14 · Cited by 1
Gut Microbiome Drives the Development of Colorectal Cancers and Potential Therapeutic Interventions
Ghosh, S., Patra, B., & Chakraborty, T. (2023) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2023.v78i02.022 · Cited by 1
Excitation et crispations autour de CRISPR : lorsque la réalité dépasse la science-fiction
Kaplan, J. (2016) · Les Cahiers de Myologie · doi:10.1051/myolog/201613015 · Cited by 1
Direct purification of CRISPR/Cas ribonucleoprotein from E. coli in a single stepPreprint
Lin, S., Qiao, J., Ma, L., & Liu, Y. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/377366 · Cited by 1
Metadata
- Authors
- Yin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., Gupta, A., Bolukbasi, M. F., Walsh, S., Bogorad, R. L., Gao, G., Weng, Z., Dong, Y., Koteliansky, V., Wolfe, S. A., Langer, R., Xue, W., & Anderson, D. G.
- Affiliations
- Koch Institute for Integrative Cancer Research At MIT (US)
- University of Massachusetts Chan Medical School (US)
- Tongji University (CN)
- The Ohio State University (US)
- Skolkovo Institute of Science and Technology (RU)
- Harvard–MIT Division of Health Sciences and Technology (US)
- Corresponding author
- Xue, Wen
- Anderson, Daniel G
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2016-02-01
- Volume
- 34
- Issue
- 3
- Pages
- 328-333
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC5423356
- OpenAlex
- W2260024370
- Cited by
- 876
- References
- 47
- Citations by year
- 2026: 26 · 2025: 56 · 2024: 44 · 2023: 52 · 2022: 90 · 2021: 108 · 2020: 110 · 2019: 104 · 2018: 128 · 2017: 112 · 2016: 46
- FWCI
- 67.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by)
- PubMed Central (acceptedVersion, cc-by)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- eScholarship@UMassChan (submittedVersion)
- Funders
- National Institutes of Health (1f32eb017625-01)
- National Eye Institute (P30EY012196)
- National Cancer Institute (5‑U54‑CA151884‑04, U54CA151884, R00CA169512, P30CA014051, P30-CA-14051)
- National Institute of Biomedical Imaging and Bioengineering (1F32EB017625, F32 EB017625)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- therapeutic genome editing, CRISPR/Cas9, lipid nanoparticle delivery, adeno-associated virus vectors, hereditary tyrosinemia, fumarylacetoacetate hydrolase
- MeSH terms
- Animals, Disease Models, Animal, Genetic Vectors, Humans, Lipids, Mutation, Viruses, Genome, Human, RNA Editing, Gene Transfer Techniques, Tyrosinemias, Mice, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
